1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CCR
  4. CCR5 Isoform

CCR5

 

CCR5 Related Products (18):

Cat. No. Product Name Effect Purity
  • HY-13004
    Maraviroc
    Antagonist 99.95%
    Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.
  • HY-13406
    TAK-779
    Antagonist 99.73%
    TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.
  • HY-14882
    Cenicriviroc
    Antagonist 99.01%
    Cenicriviroc (TAK-652) is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
  • HY-P1034
    DAPTA
    Inhibitor 98.87%
    DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities.
  • HY-14882A
    Cenicriviroc Mesylate
    Antagonist 99.04%
    Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
  • HY-152132
    CCR5 antagonist 3
    Inhibitor
    CCR5 antagonist 3 (Compound 26) is a CCR5 antagonist with an IC50 of 15.90 nM.
  • HY-152131
    CCR5 antagonist 2
    Antagonist
    CCR5 antagonist 2 (Compound 25) is a CCR5 antagonist with an IC50 of 8.34 nM.
  • HY-109593
    BMS-813160
    Antagonist 99.89%
    BMS-813160 is a potent and selective CCR2/5 dual antagonist.
  • HY-19974
    TAK-220
    Antagonist 99.95%
    TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.
  • HY-17377
    Vicriviroc maleate
    Antagonist 99.91%
    Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570).
  • HY-17450A
    Aplaviroc hydrochloride
    Antagonist 99.76%
    Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW.
  • HY-111069
    Nifeviroc
    Inhibitor 98.17%
    Nifeviroc is an orally active CCR5 antagonist.
  • HY-119101
    AZD-5672
    Antagonist
    AZD-5672 is an orally active, potent, and selective CCR5 antagonist (IC50=0.32 nM).
  • HY-117621
    PF-04634817
    Antagonist 98.87%
    PF-0463481 is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC50=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC50=470 nM).
  • HY-17450
    Aplaviroc
    Antagonist
    Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW.
  • HY-117621A
    PF-04634817 succinate
    Antagonist ≥99.0%
    PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC50=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC50=470 nM).
  • HY-111321
    Fuscin
    Inhibitor
    Fuscin, a fungal metabolite, CCR5 receptor antagonist with anti-HIV effects.
  • HY-100261
    CCR5 antagonist 1
    Antagonist
    CCR5 antagonist 1 is a CCR5 antagonist which can inhibit HIV replication extracted from WO 2004054974 A2.